Purpose. To evaluate the suitability of Galleria mellonella larvae as an in vivo model and drug-screening tool for mycobacteria infections.
INTRODUCTION
Mycobacteria species, primarily Mycobacterium tuberculosis, are major human pathogens and a significant cause of morbidity and mortality. Multidrug-resistant tuberculosis (MDR-TB) is now a global challenge, with around 480 000 new MDR-TB cases occurring in 2015 [1] . Extensively drug-resistant cases were reported in 96 countries in 2012 [2] and 'totally drug-resistant' cases have been described in several countries [3] [4] [5] [6] . Using M. fortuitum [7, 8] , M. marinum [9, 10] and M. aurum [11, 12] as surrogates for M. tuberculosis is well established, both in vitro and in vivo, but M. fortuitum and M. marinum are important infectious bacteria in their own right. Infections with either bacterium have no reporting requirements, but estimates of incidence are 4.65-5.99 cases per million persons for M. fortuitum [13] and 0.05-0.27 case per 100 000 adult patients for M. marinum [14] . These mycobacteria have similar hostpathogen interactions [15] , cell-wall profiles [11] , membrane and efflux pump proteins [16] , virulence genes [17] and drug-resistance profiles [12] to M. tuberculosis, but are much less capable of infecting an immunocompetent human and generally have a much faster growth rate.
A rapid screening model is needed to assess effective treatment combinations and expedite the discovery of novel therapies for mycobacteria. Using wax moth larvae, Galleria mellonella, as an in vivo model to assess the virulence of pathogens and the efficacy of antimicrobials is well established (reviewed in [18, 19] ). Their small size, low purchase and maintenance costs, and reduced ethical controls mean that they are accessible to most laboratories. Many experiments require minimal specialized equipment, and larvae can be incubated at 37 C and easily inoculated with precise volumes -a significant advantage over other invertebrate models, such as fruit flies and nematodes, which are not viable at 37 C for extended incubations and are awkward to inoculate. The wax moth larvae model can be a valuable screening tool to highlight treatment combinations, novel compounds and alternative therapies that can then be assessed in mammalian trials.
Compared to mammals, G. mellonella lacks an adaptive immune system, yet the invertebrate innate immune system is very robust, with complex cellular defences and the production of at least 18 antimicrobial peptides [20] . Vertebrate white blood cells and invertebrate haemocytes are not homologous, although they do have analogous roles, including wound repair [21] , cell clustering around foreign bodies [22] , innate immunity [23] , phagocytosis [24] and the production of reactive oxygen species as a defence mechanism [23] .
Using a cheap and rapid in vivo model to reliably model mycobacterial treatments is clearly attractive. Considering the advantages of using a model organism that negates the requirement for specialized laboratories and ethical approval, it is equally advantageous (for the reasons stated above) to use non-tuberculosis mycobacteria species such as M. fortuitum, M. marinum and M. aurum, since M. tuberculosis is a highly pathogenic bacterium that is capable of infecting immunocompetent individuals [25] and requires weeks of incubation before cultures are ready to use. This report aims to demonstrate the suitability of G. mellonella as a model for mycobacteria infections, allowing the application of the model as a cheap, efficient and rapid in vivo screen for antibiotic combinations and novel treatments that may be effective against M. tuberculosis infections.
METHODS

Reagents and larvae
Reagents were purchased from Sigma-Aldrich Ltd (Dorset, UK) unless stated otherwise. Antibiotics were dissolved in sterile deionized water. Larvae were purchased from UK Waxworms Ltd (Sheffield, UK), stored in the dark at 20 C and used within 7 days of receipt. Injections were performed with a 25 µl Hamilton syringe. Larvae were incubated at 37 C in Petri dishes in all experiments.
Bacteria and growth media M. fortuitum NCTC 10394 and NCTC 8573, M. marinum strain M and R356933F, and M. aurum NCTC 10437 were purchased from the National Collection of Type Cultures (Porton Down, Salisbury, UK). M. marinum R356933F was kindly provided by Michael Smith (Scottish Mycobacteria Reference Laboratory, Royal Infirmary of Edinburgh, UK).
The bacteria were cultured in a shaking incubator using Mueller-Hinton M7H9 broth enriched with albumin dextrose catalase (ADC) overnight at 37 C for the M. aurum and M. fortuitum strains, and at 27 C for approximately 36 h for the M. marinum strains. Any agar plates used were Mueller-Hinton M7H9 broth enriched with ADC supplement and 10 % agar, except for the selective plates used in the burden experiment, which included piperacillin (PIP) at 256 mg l
À1
.
Prior to all inoculations, all bacteria were washed twice and diluted to the required concentration using PBS. Heatkilling was performed in a 100 C water bath for 10 min and loss of viability confirmed by plating out as above.
Antibiotic susceptibility testing
The minimum inhibitory concentration (MIC) of each antibiotic against M. fortuitum NCTC 10394 and NCTC 8573, and M. marinum strain M and R356933F was determined using MIC strips (AMK and CIP, Oxoid, UK; EMB, INH and RIF, Liofilchem, Italy) according to the manufacturer's instructions. Cells were plated at 2.5Â10 6 c.f.u. per 90 mm plate and incubated at 27 C or 37 C as appropriate. The MIC was performed in triplicate and determined as the point on the strip where bacteria no longer grew when in contact with the paper.
Infection of G. mellonella larvae
The experiments were performed in duplicate (n=15) and the results pooled (n=30). Larvae were infected with varying inoculum sizes for each mycobacteria strain. Larvae injected with sterile PBS were included as mock-infected controls. Non-viable-bacteria control larvae received injections of heat-killed cells at a concentration equal to the largest viable cell inoculum tested. Larval survival was assessed every 24 h for 144 h and larvae were recorded as dead when they were no longer responsive to touch. Survival was plotted as Kaplan-Meir survival curves and comparisons were made using log-rank tests. Holm's correction for multiple comparisons [26] was applied.
Antibiotic toxicity was assessed by injecting larvae with 100 mg kg À1 of each and recording the survival and levels of melanization on the larval body for 144 h. For antibiotic efficacy experiments, larvae were infected and then given single treatments of antibiotic or PBS (mock-treated control) 2 h post-infection (p.i.). For combination experiments, antibiotics were prepared as a single 10 µl dose. Comparisons of survival were made using log-rank tests on KaplanMeir survival curves. In all tests P 0.05 was considered significant and Holm's correction was applied to account for multiple comparisons.
Measurement of the internal burden of mycobacteria inside infected larvae Forty larvae were infected with 10 µl of 4Â10 8 Preparation of larval suspension for plating was performed as described previously [27] . Piperacillin (PIP) was selected from a range of antimicrobials to use in selective agar plates as it inhibited the in vitro growth of micro-organisms present in the larval gut but did not affect the recovery of the colony-forming units of any of the mycobacteria used in this study (data not shown). Larval suspensions were serially diluted and plated on M7H9+ADC+PIP selective agar plates and then incubated at 27 C or 37 C as appropriate for 24-72 h until colonies were visible. 7 c.f.u. ml À1 for M. marinum). The larvae were incubated for 1 h and then injected with 30 µl Galleria saline [28] saturated with phenylthiol urea (PTU) and bled into individual sterile reaction tubes. The haemolymph was transferred to wells in a 24-well plate prefilled with 300 µl ice-cold Grace's insect medium and 13 mm round glass coverslips. The plate was incubated for 1 h in the dark in a 27 C low-speed shaking incubator. The supernatant was removed and 1 ml 3.7 % formaldehyde was added for 20 s before 300 µl 0.4 % trypan blue in PBS was added for 20 min. The coverslips were washed three times with PBS and then mounted for examination at 40Â magnification using a Delta Vision fluorescence microscope with differential interference contrast and filters for FITC (excitation 490 nm/emission 528 nm). The haemocytes were imaged through an appropriately sized z-stack to allow counting of internalized bacteria.
Ten larvae were examined for each condition, with 30 to 70 haemocytes being counted per larvae. The phagocytic rate was calculated as the percentage of the total haemocytes that had engulfed one or more bacteria. Multiple comparisons were assessed with Holm's correction.
Determination of circulating haemocyte numbers
Fifteen larvae were injected per tested condition. Larvae were infected with 10 µl of M. fortuitum NCTC 10394 or M. marinum strain M at an inoculum size of 1.0Â10 7 c.f.u. ml
À1
. This inoculum size was selected as it induced no lethality over the 48 h duration of the experiment and the collection of haemolymph from dead larvae was impractical.
Larvae were inoculated 2 h after infection with PBS, AMK (50 and 5 mg kg À1 for M. fortuitum, 50 and 2.5 mg kg À1 for M. marinum) or EMB (50 mg kg À1 for both species). Larvae were also mock-infected with 10 µl of PBS and then 2 h later with AMK (50, 5 or 2.5 mg kg À1 ) or EMB (50 mg kg
) to assess the effects of these antibiotics on circulating haemocyte numbers in the absence of infection. Unmanipulated controls were included. Three larvae were randomly selected and injected with 75 µl Galleria saline [28] at 5, 18.5, 24 and 48 h p.i. Haemolymph was bled into individual sterile reaction tubes and 10 µl was loaded onto an improved Neubauer haemocytometer and the haemocytes counted with duplicates for each sample. This experiment was performed in triplicate to give n=9 for each experimental condition. Holm's correction was applied to multiple comparisons.
RESULTS
Infection of G. mellonella larvae with viable mycobacteria results in inoculum size-dependent lethality Larvae were infected with a range of inoculum sizes of different mycobacteria. In all cases, with the exception of M. aurum NCTC 10437, the larval survival decreased as the inoculum size increased (Fig. 1a , b and d-f). M. aurum NCTC 10437 had no detrimental effect on larval survival at any of the inoculum sizes tested (Fig. 1c) . Notably, heatkilled bacteria had no detrimental effect on larval survival in any of the experiments, indicating that larval death was caused by infection with viable M. fortuitum or M. marinum. There were variations between M. fortuitum and M. marinum virulence -M. marinum required fewer bacteria (~3Â10 7 c.f.u. ml
À1
) to decrease larval survival substantially, compared to M. fortuitum, which required up to 30 times more bacteria to have the same effect.
M. marinum NCTC 2275 was not selected for continued experimentation as of the three M. marinum strains used it had the weakest virulence. M. aurum NCTC 10437 was also not investigated further as the larvae were resistant to infection.
Administration of anti-mycobacterial antibiotics enhances the survival of G. mellonella larvae infected with mycobacteria The MICs of a range of anti-mycobacterial antibiotics (AMK, CIP, EMB, INH and RIF) were measured for each of the mycobacteria to allow comparison of in vitro antibiotic susceptibility with efficacy of the same drugs versus infected larvae in vivo. The in vitro MICs are described in Table 1 . The MICs varied widely for all antibiotics tested, even between strains of the same species.
Prior to studying the efficacy of the same antibiotics in vivo, larvae were administered a high dose (100 mg kg
) of each antibiotic alone to determine if any were toxic. Compared to larvae administered PBS alone, there was no evidence of toxicity to the larvae from any of the antibiotics -survival was 100 % 144 h p.i., and no melanization was observed on The effects of a single dose 2 h p.i. of the same antibiotics (Table 1) on survival of G. mellonella larvae 144 h p.i. with mycobacteria are shown in Fig. 2 . Complete Kaplan-Meier survival curves are available in the Supplementary Data (available in the online version of this article). To readily observe any therapeutic benefit from antibiotic treatment, the larvae were infected with an inoculum of each Mycobacterium known to result in a high level of mortality (Fig. 1) .
The antibiotic doses administered were selected on the basis of pilot experiments that screened a wide range of doses for therapeutic benefit (data not shown). An upper threshold dose of 100 mg kg À1 was selected for all the antibiotics tested.
AMK was the most successful antibiotic tested, conferring significant therapeutic benefit against infections by all four mycobacteria tested (Fig. 2a) . Comparison of the effectiveness of AMK in vivo with the in vitro MICs of AMK for each bacterial strain (Table 1 ) revealed poor correlation. For example, M. marinum R356933F and M. marinum strain M had MICs of 2 and 1 mg l À1 , respectively, for AMK. In contrast, the doses of AMK required to successfully treat the in vivo infections with the same strains were reversed, with a single-dose of only 10 mg kg À1 being required for the more resistant M. marinum R356933F and a higher dose of 25 mg kg À1 being required for the more sensitive M. marinum strain M.
CIP treatment (Fig. 2b) was effective for larvae infected with the M. fortuitum strains, but displayed little efficacy versus larvae infected with either strain of M. marinum. Unlike with AMK, this observation did correlate with the MIC values for each strain (Table 1) , as both M. fortuitum strains were far more sensitive to CIP than the M. marinum strains.
EMB was the least effective antibiotic in these experimentssurvival at 144 h was almost invariably indistinguishable from that for the mock-treated control (PBS) (Fig. 2c) . The 
correlation between the in vitro and in vivo efficacies of EMB was poor.
INH is largely ineffective for larvae infected with M. fortuitum NCTC 8573 (Fig. 2d) , which is supported by the in vitro data (Table 1) . Survival of larvae infected with M. fortuitum NCTC 10394 is statistically significant, and the MIC results suggest sensitivity to INH, but overall survival was low even at the highest doses tested. This contrasts with larvae infected with M. marinum -both strains responded positively to INH treatment, and high doses conveyed a long-lasting survival advantage, supported by the sensitivity to INH in vitro.
RIF significantly improved larval survival after infection with M. marinum (Fig. 2e ) and this correlated with the in vitro MICs (Table 1) . However, the M. fortuitum strains had differing responses to RIF. Mycobacterium fortuitum NCTC 10394 is unresponsive even at high doses, whereas larval survival significantly improved when M. fortuitum NCTC 8573 was treated with similar doses. Notably, this did correlate with the MICs because M. fortuitum NCTC 8573 was highly sensitive to RIF in vitro, whilst M. fortuitum NCTC 10394 had the highest MIC of any of the mycobacteria strains tested.
To conclude, in cases where the administered antibiotic enhanced larval survival in vivo, this occurred in a dosedependent manner, with some doses resulting in near 100 % survival compared to mock-treated controls. However, not all antibiotics were efficacious in vivo and the degree of correlation between the in vitro sensitivity of the mycobacteria to the drugs and their ability to enhance larval survival in vivo was variable.
In subsequent experiments, M. fortuitum NCTC 10394 and M. marinum strain M were used, as they are the type strains for their species.
Administration of AMK, CIP or INH to larvae infected with mycobacteria reduces the overall bacterial burden within the larvae The effect that efficacious doses of antibiotics had on the bacterial burden within the larvae was measured by enumerating viable bacteria in homogenates of larvae that had been exposed to bacteria and PBS or antibiotic. Doses of AMK, CIP and INH were selected that were previously shown to confer almost full survival (Fig. 2 ) on larvae infected with inoculum sizes of M. fortuitum NCTC 10394 or M. marinum strain M that were shown to be lethal to untreated larvae over a period of 144 h (Fig. 1) .
Infection with M. fortuitum NCTC10394 (4.0Â10 8 c.f.u. ml
) resulted in a large drop in viable bacteria over the first 5 h p.i. (Fig. 3a) . In contrast, infection with M. marinum strain M (3.0Â10 7 c.f.u. ml
) only led to a minor decrease in bacterial numbers over the same time period (Fig. 3b) . This obvious difference in the ability of the innate immune system to eliminate the two mycobacteria strains could explain why larvae need a higher inoculum of M. fortuitum cells to cause significant larval death compared to the M. marinum species (Fig. 1) . Nonetheless, viable mycobacteria were recovered from both mock (PBS) and antibiotic-treated larvae throughout the entire duration of the experiment (Fig. 3) , despite the fact that the doses of antibiotics administered permitted almost full survival of infected larvae (Fig. 2) . Bacterial burden is mitigated by treatment with the selected antibiotics, but viable bacteria were still detected 144 h p.i. with all antibiotics tested. At some time points, the difference in internal mycobacterial burden between antibiotic-treated and mock-treated larvae was significantly reduced, potentially accounting for the observed efficacy of these antibiotics (Fig. 2) .
Infecting mycobacteria are phagocytosed by G. mellonella haemocytes, but phagocytosis is reduced by exposure to antibiotics To determine the fate of mycobacteria in G. mellonella larvae, and how this was influenced by antibiotic therapy, bacterial phagocytosis was measured by microscopy (Fig. 4) . The procedure required to label the mycobacteria with FITC meant that the infecting bacteria were dead (see the Methods section). Nonetheless, FITC-labelling permitted the visualization of internalized mycobacteria and a representative image of larval haemocytes that have phagocytosed bacteria is shown in Fig. 4(a) . Groups of larvae were administered a single 10 µl dose of either PBS, 2.5, 5 or 50 mg kg À1 AMK, or 50 mg kg À1 EMB. These doses of AMK were selected because 2.5 and 5 mg kg À1 were shown to have no therapeutic benefit for infected larvae compared to 50 mg kg
, which resulted in almost complete survival (Fig. 2) . Similarly, 50 mg kg À1 EMB was selected because this dose had little therapeutic benefit. In this way the effect of therapeutic and non-therapeutic doses of antibiotics on phagocytosis could be measured. After 10 min the larvae administered with either 10 µl PBS or antibiotics were then inoculated with FITC-labelled mycobacteria and phagocytosis was measured after 1 h at 37 C (Fig. 4b) .
In larvae exposed to PBS only, over 40 % of haemocytes compared to 21 % had engulfed one or more M. fortuitum NCTC 10394 or M. marinum strain M cells, respectively (Fig. 4b) . This reflected the higher infecting inoculum of M. fortuitum NCTC 10394 (4.0Â10 8 c.f.u. ml
) compared to M. marinum strain M (3.0Â10 7 c.f.u. ml
). For both strains, exposure to a dose of AMK that was shown to be fully efficacious (50 mg kg
: Fig. 2 ) resulted in a significant reduction in phagocytosis compared to the PBS-treated controls. Phagocytosis dropped to 21 and 6.9 % for M. fortuitum NCTC 10394 or M. marinum strain M cells, respectively. The effect of nonefficacious doses of AMK and EMB on phagocytosis differed between M. fortuitum NCTC 10394 and M. marinum strain M cells. For M. fortuitum NCTC 10394, these doses had no impact on phagocytosis compared to larvae exposed to PBS. In contrast, ineffective doses of 2.5 mg kg À1 AMK and 50 mg kg À1 EMB reduced phagocytosis of M. marinum strain M cells to a similar extent as the efficacious dose of 50 mg kg À1 AMK (Fig. 4b) .
In summary, the larval response in terms of phagocytosis was dependent on the infecting species of mycobacteria, and phagocytosis was also reduced by exposure to both efficacious and non-efficacious doses of antibiotics in a speciesdependent fashion.
Administration of antibiotics to uninfected larvae and larvae infected with mycobacteria induces a significant increase in the number of circulating haemocytes The reduction in phagocytosis induced by exposure to antibiotics could perhaps be explained by changes in the overall numbers of circulating haemocytes. Thus, the effect of exposure to the same doses of AMK and EMB administered in Fig. 4 on circulating haemocytes was measured using microscopy ( Figs 5 and 6 ).
Larvae were mock-infected with sterile PBS and then injected 2 h later with PBS, AMK or EMB. Relative to PBS treatment, exposure to all doses of each of the antibiotics resulted in a significant, transient increase in the number of circulating haemocytes within the 3 h after antibiotic administration that disappeared by 24 h (Fig. 5) . The transient increase in haemocyte number induced by AMK after 5 h was dose-dependent.
Similarly, when larvae were infected with a viable inoculum of M. fortuitum NCTC 10394 and M. marinum strain M cells, followed by administration of PBS or the same antibiotic doses of AMK and EMB used previously (Figs 4 and 5) , the circulating haemocyte numbers were again significantly higher after 5 h than in larvae mock-infected with PBS (Fig. 6) . Mock-treatment with PBS also resulted in an increase in haemocytes, but this was much smaller than that induced by antibiotic treatment. As before, the antibioticinduced increase in haemocyte numbers peaked at 5 h and declined noticeably thereafter (Fig. 6 ).
In summary, the previous data revealing that antibiotics reduced the phagocytic rate of FITC-labelled dead mycobacteria (Fig. 4) could perhaps be explained by the increase in circulating haemocyte numbers that was induced by exposure to the antibiotics alone (Fig. 5) or by antibiotics administered to larvae infected with viable mycobacteria (Fig. 6 ). For example, increased numbers of haemocytes could mean that many may not encounter bacteria to phagocytose, thereby reducing the overall quantity of haemocytes containing bacteria. 
Antibiotic combination treatments provide greater therapeutic benefit to larvae infected with mycobacteria than antibiotic monotherapy Treatment of M. tuberculosis infections usually involves the administration of combinations of antibiotics for optimal therapy. To mimic combination therapy with infected G. mellonella larvae, and to observe whether typical combination treatments were also more efficacious in this model system, three antibiotic combinations were selected using WHO treatment guidelines [29] . Thus, the therapeutic benefit conferred by three multiple-drug combinations was studied: one triple combination (EMB+INH+ RIF) and two quadruple combinations (AMK+EMB+INH+RIF and CIP+EMB+INH+RIF) (Fig. 7) . The doses of the individual antibiotics administered within the combination regimens were selected on the basis that they provided minimal therapeutic benefit when given as monotherapy to larvae infected with mycobacteria (Fig. 2) . When these non-efficacious doses were combined, larval survival improved significantly compared to mock-treated groups (PBS) (Fig. 7) and to larvae administered with a dose of each individual drug (Fig. 2) . Thus, the larval model reflects the enhanced efficacy of antibiotics administered in combinations as practised in clinical settings.
DISCUSSION
The data reported here show that G. mellonella larvae could be employed as a valuable in vivo infection model for several mycobacteria species and allow the therapeutic effects of antibiotic treatments to be quantified.
The majority of the mycobacteria examined can kill G. mellonella larvae, and the number of viable infecting bacteria correlates negatively with larval survival. The exception is M. aurum NCTC 10394, although M. aurum is exclusively reported as being infectious in immunocompromised humans [30, 31] (unlike M. fortuitum [32, 33] and M. marinum [14, 34] ), so non-pathogenicity in immunocompetent larvae is perhaps unsurprising.
Ethambutol, isoniazid and rifampicin were selected for their historic inclusion in standard TB treatment regimens [35] , and amikacin and ciprofloxacin were selected for their use as second-line treatments for MDR-TB [36] . All five have been used with M. fortuitum [32, [37] [38] [39] [40] [41] and M. marinum [14, 42, 43] in vitro and in vivo, although the in vivo experiments have predominantly used combination treatments. When used to treat human infections, amikacin can be used at 15 mg kg
À1
for M. fortuitum infections [32] or 400 mg daily for M. marinum [44] . Ciprofloxacin has been used at approximately 8 mg kg À1 for M. fortuitum infections [45] and 500 mg twice daily for M. marinum [46] . Ethambutol, isoniazid and rifampicin are not prescribed for M. fortuitum infections, although daily doses of ethambutol at 25 mg kg À1 and rifampicin at 600 mg are a well-established treatment for M. marinum [47] , and isoniazid at 10 mg kg À1 has been shown to be an effective treatment for M. marinum in zebrafish [48] . Whilst the efficacious doses of these drugs in G. mellonella larvae were different, they were at least comparable and of a similar order of magnitude.
The effective antibiotics generally improved larval survival in a dose-dependent manner compared with mock-treated larvae (Fig. 2) . However, varied sensitivity to each antibiotic was observed between strains and several antibiotics had no ) (b), followed by treatment 2 h p.i. with a single dose of either PBS, antibiotic monotherapy or antibiotic combinations. The antibiotic monotherapy doses for M. fortuitum were 5 mg kg À1 AMK, 2.5 mg kg À1 CIP, 100 mg kg À1 EMB, 5 mg kg À1 INH and 30 mg kg À1 RIF, and for M. marinum they were 2.5 mg kg À1 AMK, 50 mg kg À1 CIP, 100 mg kg À1 EMB, 5 mg kg À1 INH and 10 mg kg À1 RIF. The combination treatments consisted of the same drug concentrations as above, but pooled to a make a single combination dose. The data show the mean survival ±SEM after 144 h. * indicates a significant increase in survival for combination therapy compared to each individual monotherapy. P<0.05, log-rank test on complete Kaplan-Meier curves with Holm's correction applied for multiple comparisons.
Entwistle and Coote, Journal of Medical Microbiology 2018;67:585-597 therapeutic effect at the highest dose tested. Combination therapies that included some of the ineffective antibiotics improved overall efficacy -some combinations gave almost 100 % larval survival across the 144 h experiment. Considering the necessity of employing antibiotic combinations when treating patients infected with mycobacteria, this result is key to indicating the potential role of G. mellonella in testing further novel combination treatments. In addition, measurement of the bacterial burden (Fig. 3) indicated that efficacious doses of antibiotics that permitted almost full survival of the infected larvae only reduced the overall numbers of bacteria within the larvae without eliminating them. This implies that a certain threshold number of mycobacteria are required to cause larval death and that the larvae are readily able to survive despite still being infected with bacterial numbers that are below this apparent lethal threshold. It is not clear from this work what contribution the direct inhibitory action of the drugs on the infecting bacteria makes to the measured efficacy of the antibiotics, and what contribution is made by the apparent stimulation of the innate immune system (in the form of increased haemocyte numbers; Figs 5 and 6) that is triggered upon exposure to the antibiotics. It would seem likely that both actions contribute to the measured efficacy of the drugs.
Human phagocytic cells have been assessed against a multitude of antimicrobials and pathogens to determine whether phagocytosis is enhanced, supressed or unaffected (reviewed in [49] ), and is it well established that a number of medications can reduce [50] or increase [51] the number of circulating immune cells in humans. A reduction in the number of circulating white blood cells is a very rare side-effect when using anti-tuberculosis medications [52] -there is no suggestion that any of the drugs in this study cause a reliable change in the number of circulating immune cells in humans. Interactions between antibiotics and the larval immune system may explain why antibiotics cause such a significant increase in the number of circulating haemocytes in the hours post-injection (Fig. 5) . A similar response has been shown when using antifungals with G. mellonella elsewhere [53, 54] . Given that the increase is not seen when larvae are mock-treated with PBS, this suggests that antimycobacterials trigger a non-specific immune response. Increased numbers of circulating haemocytes has been shown to correlate with improved larval survival for fungal infections [55] , yet here the antibiotic EMB increased haemocyte density but did little to improve larval survival, so this correlation may not be universally applicable.
The lack of correlation between the in vitro efficacy of the antibiotics (Table 1 ) and the in vivo data (Fig. 2) is not necessarily detrimental to the conclusions of this study. A useful application of this model is to test drugs that have only been examined in vitro to determine possible variances in the in vivo results, and it is vital not to overly extrapolate in vitro data to predict in vivo results, as there are often discrepancies between the two.
The existing whole-organism models for mycobacterial, particularly M. tuberculosis, infections include mice, rats, guinea pigs, rabbits, cattle and primates. However, all of these present problems with cost, housing requirements, operating regulations and ethical concerns. Non-mammalian models can also be a useful tool. For example, zebrafish are not natural hosts of M. tuberculosis, but M. marinum infections eventually produce lipid-rich and necrotic granulomas [56] in adult and larval fish, despite the immature fish larvae having no adaptive immune system at that developmental stage [10] .
Drosophila melanogaster (fruit fly) is becoming a well-established model for M. marinum [57] . Infected flies show evidence of 'wasting' [58] , a key symptom in humans. Fly haemocytes engulf M. marinum that replicate inside the haemocytes and are eventually released and then found extracellularly to the host cells [59] similar to M. tuberculosis with human immune cells. Unfortunately, fruit flies are reared at [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] C and are difficult to inoculate with specific volumes. Circulating haemocytes can only be collected from fly larvae, [60] , meaning that the short-term effects of infection on circulating haemocytes can only be examined in larvae -long-term experiments must use adult flies [59] .
For these reasons, Galleria mellonella larvae are an attractive model organism for screening novel compounds against mycobacterial infections. They thrive at 37 C, can be easily and consistently inoculated with specific quantities of bacteria and drugs, and haemocytes can be collected from their haemolymph long after infection. Similarly to D. melanogaster, experiments are limited to the life cycle of the larvae, and larvae are unlikely to be of use in persistence models of latent TB infections. However, considering the pressure to locate new and novel compounds to treat mycobacterial infections, especially drug-resistant strains, having access to a convenient in vivo model early in the drug discovery and development timeline could be invaluable. We suggest that G. mellonella would be a valuable tool for testing compounds with efficacy against mycobacteria and may provide useful evidence to support further work with clinically relevant cell lines or small-mammal trials.
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